MindWalk reports strong growth in Q3 2026 and strengthens its AI strategy for drug discovery
MindWalk Holdings Corp. ,a company specializing in AI-assisted biologic discovery and drug development, announced its financial results for the third quarter of fiscal year 2026 , which ended January 31, 2026. The company continues its growth trajectory while developing its AI platforms and therapeutic programs.
Solid revenue growth
In the third quarter of 2026 , MindWalk recorded revenue of $4.2 million , a 52% increase compared to the $2.7 million generated in the third quarter of the previous fiscal year. This marks the third consecutive quarter of year-over-year growth for the company.
Revenue in the United States doubled year-over-year , reaching $2.6 million , compared to $1.3 million in Q3 2025. For the first nine months of the fiscal year , total revenue amounted to $11.4 million , up 45% compared to $7.9 million in the same period last year.
The cumulative gross margin also improved to 58% , compared to 53% a year earlier. The gross margin for the quarter was 59% .
A net loss that has decreased significantly
The net loss from continuing operations for the quarter was $3.9 million , compared to $22 million in Q3 2025. However, the prior year’s loss included an asset impairment of $21.2 million , which explains the significant difference.
As of January 31, 2026 , the company had $14.2 million in cash and cash equivalents .
First recurring contract for the LensAI platform
MindWalk has reached a significant milestone with the signing of the first annual contract for its LensAI platform with its largest enterprise AI client . This coincome, la facturation étant désormais effectuée mensuellement.
According to Jennifer Bath, CEO and President of MindWalkThis contract reflects therevenus basés sur des projetshasrevenus contractuels récurrents, All
To support this strategy, MindWalk has established oand chose towithdraw from thisin order to concentrate his
Launch
The company also announced the launch of B, a plthatfrom
VHH nanobodies, lacking a light chain, avoid chain pairing problems that often limit the development of bispecific antibodies.This segmentplus de 50 milliards de dollars d’ici 2030.
A scientific study published in Biomacromolecand led to
- neutralizeFor
- the importance of selection, rather than on
MindWalk also holds the first commercialization rights to the intellectual property i
Advances in the
Dengue vaccine
The dengue vaccine program is progressing with the completion of in-immunization studiesThe results confirmed that the immunized animals pand.
Neutral tests devraient prochainement évaluer la capacité du vaccin à neutraliser les différents sérotypes.
Programme GLP-1
MindWalk also confirmed the in vitro activation ofby acelle du sémaglutide, you are the leader29 billion.
The program also explores a sor
Programme contre la grippe
In its flu prevention program, the LensAI platformanalyzed more than 2, y compris d’origine aviaire et porcine, permettant d’identifier a characteristicin all
The lead vaccine candidate is currently being manufacturedin order to pr
Vers un financement au niveau des actifs
MindWalk also explores the implementation of program-specific funding structures , in particular forGLP-1, dengue et grippe.preserve.
Next t
MindWalk will organize a teleconference.the12 mars 2026 à 10h30 (heure de l’Est), accessible en direct via la section relations investisseurs du site de la société.